Absence of high-risk HPV 16 and 18 in Chinese patients with oral squamous cell carcinoma and oral potentially malignant disorders by unknown
RESEARCH Open Access
Absence of high-risk HPV 16 and 18 in
Chinese patients with oral squamous cell
carcinoma and oral potentially malignant
disorders
Xiao-Jie Chen, Kai Sun and Wei-Wen Jiang*
Abstract
Background: The critical role of human papillomavirus (HPV) in cancer has been recognized, but the involvement
of HPV in oral squamous cell carcinoma (OSCC) and oral potentially malignant disorders (OPMD) is still controversial.
The aim of this study was to identify and verify the prevalence of high-risk HPV infection (HPV16 and 18) in Chinese
patients with OSCC or OPMD using real-time PCR and DNA sequencing.
Methods: Paired tissue and serum DNA samples were extracted from 40 Chinese patients with OSCC and 59 with
OPMD. A SYBR Green-based real-time PCR assay was developed to detect the E6 gene of HPV16 and HPV18.
Suspicious positive samples were then sequenced to eliminate false positives.
Results: We found that none of the tissue and serum samples of OSCCs and OPMDs were positive for HPV16 E6
or 18 E6, using both real-time PCR and DNA sequencing. Overall, 3 of 198 (1.52 %) and 7 of 198 (3.54 %) samples
were false-positive for HPV16 E6 and HPV18 E6, respectively, using real-time PCR.
Conclusion: The lack of HPV16 and HPV18 detected in this study indicates that high-risk HPV 16 and 18 infections
are uncommon in Chinese patients with OSCC and OPMD. Real-time PCR followed by DNA sequencing for HPV DNA
detection is an effective strategy to rule out false positives.
Keywords: HPV16, HPV18, Oral squamous cell carcinoma, Oral potentially malignant disorders
Background
Head and neck squamous cell carcinoma (HNSCC), which
includes squamous cell carcinomas of the oral cavity, oro-
pharynx, larynx, and hypopharynx, is the sixth most com-
mon cancer worldwide [1, 2]. Two main risk factors
related to HNSCC are tobacco use and alcohol consump-
tion [3]. Recently, investigators have suggested that human
papillomavirus (HPV) is a potential etiological factor of
HNSCC in patients who do not smoke or drink alcohol,
particularly in oropharynx squamous cell carcinoma
(OPSCC) [4, 5]. The oncogenic proteins E6 and E7 of
high-risk HPVs, such as HPV16 and HPV18, are consid-
ered to be associated with the carcinogenic process of
OPSCC by inactivating the tumor suppressor genes p53
and Rb [6, 7]. However, the rate of detecting HPV in
OSCC varies widely (0–100 %), and the role of HPV in
oral carcinogenesis has long been controversial [8].
HPV has been detected in not only cervical cancer but
in cervical premalignant lesions as well, and the detection
rate is known to increase with the severity of disease ab-
normality [9]. Oral lesions and conditions associated with
a risk of malignant transformation have been referred to
as oral potentially malignant disorders (OPMD) and in-
clude oral leukoplakia (OLK), lichen planus, and erythro-
plakia [10]. Recent studies have revealed a varying rate of
detected HPV in OPMD [8]. A better understanding of
the true presence of HPV in OSCC and OPMD may thus
contribute to further studies of these diseases.
Different techniques have been used to detect HPV,
including in situ hybridization (ISH), Southern blot
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hybridization, dot blot hybridization, hybrid Capture 2
(hc2), conventional PCR, and real-time PCR [11]. ISH,
Southern blot and dot blot hybridization are time-con-
suming procedures that require relatively large amounts of
purified DNA [11]. Hc2 assay cannot genotype single HPV
subtypes [11]. Of these methods, studies using PCR tech-
niques have reported a higher sensitivity for HPV detection
[12]. However, conventional PCR assays may have a
lower sensitivity and specificity [11]. Real-time PCR has
a sensitivity of 92 % and a specificity of 97 % in detect-
ing HPV and is able to genotype and quantitate HPV
viral load [13].
The aim of our study was to identify the detection rate
of high-risk HPV types 16 and 18 in Chinese patients




A total of 99 patients including 40 OSCC and 59 OPMD pa-
tients were enrolled from the Department of Oral Mucosal
Diseases and the Department of Oral Maxillofacial Surgery
at the Shanghai 9th People’s Hospital, Shanghai Jiao Tong
University School of Medicine. Paired tissue and serum
samples were collected from each patient. Tissue samples
were immediately frozen at −80 °C after surgery. Serum was
obtained from the supernatant of the collected whole blood
and stored at −80 °C until processing. Histological diagnoses
were made by one pathologist who was on duty and con-
firmed by a superior pathologist according to the World
Health Organization criteria [14, 15]. This study was ap-
proved by an Independent Ethics Committee of Shanghai
Ninth People's Hospital affiliated to Shanghai Jiao Tong
University, School of Medicine (#200703), and signed in-
formed consent was obtained from each patient. The base-
line characteristics of the patients are presented in Table 1.
Cell culture
The CAL27 cell line was obtained from the American
Type Culture Collection (ATCC, Rockville, MA, USA)
and was grown in Dulbecco’s Modified Eagle Medium
(HyClone, Logan, UT, USA) containing 10 % fetal bo-
vine serum (FBS) and 1 % penicillin-streptomycin solu-
tion at 37 °C in 5 % CO2.
DNA extraction
Twenty 20-μm sections were cut from the frozen tissue
samples, and DNA was extracted using the QIAamp
DNA Micro Kit (Qiagen, Düsseldorf, Germany). Serum
DNA extraction was performed using the QIAamp DNA
Blood Mini Kit (Qiagen, Düsseldorf, Germany). CAL27
cells were detached by trypsinization and extracted
DNA with QIAamp DNA Mini Kit (Qiagen, Düsseldorf,
Germany). The plasmid pB-actin 16 E6 and pB-actin 18
E6 were bought from Addgene (Cambridge, MA, USA).
Plasmid DNA was extracted using the QIAfilter MidiKit
(Qiagen, Düsseldorf, Germany). Purified plasmid DNA were
sequenced and blasted with HPV16 E6 (NC_001526.2) and
HPV18 E6 (NC_001357.1) NCBI reference sequence. The
extracted DNA was stored at −80 °C until further use.
Real-time PCR and sequencing
Real-time PCR was performed by LightCycler 480 SYBR
Green I Master (Roche, Basel, Switzerland) together with
0.5 μmol/L of each primer and 50 ng DNA in a 10 μl re-
action were utilized. Positive controls were performed,
which including HPV plasmid DNA, HPV containing
cell line DNA and small amount of plasmids added to
clinical sample DNA (Fig. 1). Negative controls were also
performed, which including pure water, pure water in-
stead of 2 ×master mixture, pure water instead of positive
control DNA (Fig. 1). A standard curve was developed for
both HPV16 E6 (Fig. 2a) and HPV18 E6 (Fig. 2b) using a
series of 10-fold diluted plasmid DNA 1 ng to 0.1 pg. The
quantitated data was normalized by beta-actin (ACTB)
using CAL27 genomic DNA. The reaction was performed
by initiation at 95 °C for 5 min followed by 35 cycles of
95 °C for 10 s, 60 °C for 20 s and 72 °C for 10 s. Each sam-
ple was performed in triplicate. A sample was considered
positive for HPV infection if two or three wells of the trip-
licate showed an amplifying curve. It was under suspicion
if the amplifying curve was detected later than the 30th
cycle of the reaction or had a deformed shape. The suspi-
cious samples of HPV16 E6 or HPV18 E6 were then se-
quenced to rule out false positives. All primers are shown
in Table 2.
Results
Real-time PCR was conducted to detect HPV16 E6 and
HPV18 E6 DNA. We found that zero of the 99 tissue sam-
ples (0 %) showed a standard amplifying curve for HPV 16
E6, but a few samples showed late or deformed amplifying
curves in one of the triplicates, which were clearly not
considered to be positive (Fig. 3a). Thirty-nine of 40
OSCC and 57 of 59 OPMD serum samples did not show a
standard amplifying curve for HPV 16 E6 using real-time
PCR, but 1 OSCC and 2 OPMD serum samples had a late
or deformed amplifying curve in two or three wells of the
triplicate that was suspicious (Fig. 3b). In addition, 36 of
40 OSCC and all 59 OPMD tissue samples were negative
for the standard amplifying curve of HPV 18 E6, but 4
OSCC tissue samples presented a late and deformed amp-
lifying curve in two or three wells of the triplicate (Fig. 3c).
Thirty-nine of 40 OSCC and 57 of 59 OPMD serum sam-
ples were negative for the standard amplifying curve of
HPV 18 E6, but 1 OSCC and 2 OPMD serum samples
had late and deformed amplifying curves in two or three
wells of the triplicate (Fig. 3d). DNA sequence analysis
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Table 1 The baseline characteristic of patients
ID Diagnosis Age Gender Smoking Alcohol Stage
TNMa
Notes Tumor Site Type
CXJ 1 OSCC 77 M Past Never real-time PCR Tongue
CXJ 2 OLK 48 F Never Sometimes real-time PCR Gingiva
CXJ 3 OLK 36 M Current Current real-time PCR Buccal
CXJ 4 OSCC 63 M Never Past real-time PCR Tongue
CXJ 5 OSCC 54 M Current Past real-time PCR Buccal Papillary
CXJ 6 OSCC 60 M Current Current real-time PCR Buccal
CXJ 7 OSCC 41 M Current Current real-time PCR Tongue
CXJ 8 OSCC 53 M Past Current real-time PCR Buccal
CXJ 9 OSCC 41 M Current Current real-time PCR Floor of mouth
CXJ 10 OSCC 69 F Never Never T1M0N0 real-time PCR & DNA sequencing (18 ZDNA) Gingiva
CXJ 11 OSCC 56 M Current Never real-time PCR & DNA sequencing (16 SDNA) Buccal
CXJ 12 OSCC 60 F Never Never real-time PCR Gingiva
CXJ 13 OSCC 58 M Current Sometimes real-time PCR Gingiva
CXJ 14 OSCC 57 F Never Never T2N0M0 real-time PCR Tongue
CXJ 15 OSCC 55 M Sometimes Sometimes real-time PCR Hard palate Papillary
CXJ 16 OSCC 75 M Never Sometimes real-time PCR Buccal
CXJ 17 OSCC 66 F Never Never T4N1M0 real-time PCR Buccal
CXJ 18 OSCC 63 M Never Never T4N0M0 real-time PCR Buccal
CXJ 19 OSCC 43 M Current Current T4N0M0 real-time PCR Gingiva
CXJ 20 OLK 65 M Never Sometimes real-time PCR Hard palate
CXJ 21 OLK 56 M Current Sometimes real-time PCR Buccal
CXJ 22 OLK 78 F Never Never real-time PCR Tongue
CXJ 24 OSCC 59 M Current Current real-time PCR Gingiva
CXJ 25 OSCC 54 F Never Never T1N0M0 real-time PCR Tongue
CXJ 26 OSCC 72 M Never Never T3N0M0 real-time PCR Tongue
CXJ 27 OSCC 75 F Never Never T1N0MO real-time PCR Tongue
CXJ 28 OSCC 40 M Sometimes Never real-time PCR Gingiva
CXJ 30 OLK 56 F Never Never real-time PCR & DNA sequencing (16 SDNA) Gingiva
CXJ 31 OLK 60 M Current Never real-time PCR Gingiva
CXJ 32 OSCC 44 M Current Current real-time PCR Floor of mouth
CXJ 33 OLK 65 M Never Never real-time PCR Buccal
CXJ 34 OSCC 81 M Never Never real-time PCR Lip
CXJ 35 OLK 63 M Never Never real-time PCR Gingiva
CXJ 36 OSCC 58 F Never Never real-time PCR Tongue
CXJ 37 OLK 72 M Never Never real-time PCR Gingiva
CXJ 38 OLK 75 M Never Never real-time PCR Buccal
CXJ 39 OLK 73 M Past Never real-time PCR Tongue
CXJ 40 OSCC 60 F Never Never real-time PCR Buccal
CXJ 41 OLK 36 M Never Sometimes real-time PCR Gingiva
CXJ 42 OLK 57 F Never Never real-time PCR Buccal
CXJ 43 OLK 51 M Past Past real-time PCR Tongue Verrucous
CXJ 44 OLK 54 M Past Never real-time PCR Gingiva
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Table 1 The baseline characteristic of patients (Continued)
CXJ 45 OLK 56 M Never Sometimes real-time PCR Tongue
CXJ 46 OLK 66 F Current Never real-time PCR Gingiva
CXJ 47 OLK 62 M Never Past real-time PCR Tongue
CXJ 48 OLK 50 F Never Never real-time PCR Gingiva
CXJ 49 OSCC 63 M Current Sometimes real-time PCR Buccal
CXJ 50 OLK 53 F Never Never real-time PCR Tongue
CXJ 51 OLK 54 M Current Past real-time PCR Soft palate Verrucous
CXJ 52 OLK 30 M Current Sometimes real-time PCR Tongue
CXJ 53 OLK 62 M Current Sometimes real-time PCR Soft palate
CXJ 54 OLK 64 F Never Never real-time PCR Buccal
CXJ 55 OSCC 70 M Past Current real-time PCR Buccal
CXJ 56 OLK 50 F Never Never real-time PCR & DNA sequencing (16 SDNA,
18 SDNA)
Tongue
CXJ 57 OSCC 73 F Never Never real-time PCR & DNA sequencing (18 SDNA) Buccal
CXJ 58 OLK 59 F Never Never real-time PCR Tongue
CXJ 59 OLK 62 F Never Never real-time PCR Gingiva
CXJ 60 OLK 57 F Current Never real-time PCR Tongue
CXJ 61 OLK 51 M Current Never real-time PCR Tongue
CXJ 62 OLK 50 F Never Never real-time PCR Tongue
CXJ 63 OSCC 67 M Current Never real-time PCR Buccal
CXJ 64 OLK 64 M Never Never real-time PCR Tongue
CXJ 65 OLK 45 F Never Never real-time PCR Gingiva
CXJ 66 OLK 60 M Never Never real-time PCR Buccal
CXJ 67 OLK 66 F Never Never real-time PCR Tongue
CXJ 68 OSCC 38 M Current Sometimes real-time PCR Tongue
CXJ 69 OSCC 61 M Past Past real-time PCR & DNA sequencing (18 ZDNA) Buccal
CXJ 70 OLK 52 F Never Never real-time PCR Tongue
CXJ 71 OLK 35 M Past Sometimes real-time PCR Buccal
CXJ 72 OLK 58 F Never Never real-time PCR Buccal
CXJ 73 OLK + EK 37 M Past Past real-time PCR Tongue
CXJ 74 OSCC 34 M Current Current real-time PCR Tongue
CXJ 75 OSCC 53 M Current Current real-time PCR Tongue
CXJ 76 OLK 71 F Never Never real-time PCR Tongue
CXJ 77 OSCC 58 F Never Never real-time PCR Tongue
CXJ 78 OLK 58 F Never Never real-time PCR Buccal
CXJ 79 OLK + EK 37 F Never Never real-time PCR Tongue
CXJ 80 OLK 53 M Past Current real-time PCR Tongue
CXJ 81 OSCC 58 M Past Sometimes real-time PCR Tongue
CXJ 82 OLK 55 F Never Never real-time PCR Tongue
CXJ 83 OLK 53 M Current Current real-time PCR Tongue
CXJ 84 OLK 53 M Current Current real-time PCR Hard palate Verrucous
CXJ 85 OLK 54 F NA NA real-time PCR Tongue
CXJ 86 OLK 54 F Never Never real-time PCR Tongue
CXJ 87 OLK 63 M Sometimes Current real-time PCR Tongue
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was then performed on the suspicious samples, which
found that all of the samples sequenced were negative for
HPV16 and HPV18. Overall, 3 of 198 (1.52 %) and 7 of
198 (3.54 %) samples were false-positive for HPV16 E6
and HPV18 E6, respectively, using real-time PCR. Overall,
none of the OSCC or OPMD cases were positive for HPV
16 or18 in our study.
Discussion
In the past few decades, there has been speculation world-
wide about the role of HPV in the pathogenesis of
HNSCC. The most commonly detected HPV, HPV16, ac-
counts for 90 % of the HPV DNA-positive cases in
HNSCC, followed by HPV18 and other high-risk subtypes
[16]. However, the detection rate of HPV in OSCC and
OPMD varies widely and remains controversial [8, 17].
This variation may due to differences in the types of sam-
ple, detection methods or geographic locations [8, 18].
Therefore, confirming the HPV infection rate in OSCC
and OPMD cases may contribute to the study of carcino-
genesis in the oral cavity [19, 20]. In this study, we used
real-time PCR to detect HPV16 and HPV18 in paired
Table 1 The baseline characteristic of patients (Continued)
CXJ 88 OLK 72 M Never Current real-time PCR Gingiva
CXJ 89 OLK 79 F Never Never real-time PCR Buccal
CXJ 90 OLK 55 M Past Sometimes real-time PCR Tongue
CXJ 91 EK 45 F Never Never real-time PCR Buccal
CXJ 94 OLP 54 F Never Never real-time PCR Buccal
CXJ 95 OLP 54 F Never Never real-time PCR & DNA sequencing (18 SDNA) Buccal
CXJ 96 OLP 29 M Current Sometimes real-time PCR Buccal
CXJ 97 OLP 40 F Never Never real-time PCR Buccal
CXJ 98 OLP 58 F Never Never real-time PCR Buccal
CXJ 99 OLP 28 M Current Never real-time PCR Buccal
CXJ 100 OSCC 28 M Current Current real-time PCR & DNA sequencing (18 ZDNA) Buccal
CXJ 101 OSCC 62 F Never Never real-time PCR Gingiva
CXJ 102 OSCC 68 M Never Never real-time PCR Tongue
CXJ 103 OSCC 59 M Never Never real-time PCR & DNA sequencing (18 ZDNA) Buccal
OSCC oral squamous cell carcinoma, OLK oral leukoplakia, OLP oral lichen planus, EK oral erythroplakia, ZDNA tissue DNA, SDNA serum DNA, NA data not available
aUnion for International Cancer Control; T, tumor size; N, lymph node; M, Metastasis
A B
Fig. 1 Positive and negative controls for HPV16 and HPV 18 with real-time PCR. a Positive and negative controls for HPV16; b Positive and
negative controls for HPV18. Standard curve 1–5, 10-fold diluted HPV16 E6 or HPV18 E6 plasmid DNA ranging from 1 ng/well to 0.1 pg/well.
Positive control 1, cilnical DNA sample added with 0.1 pg HPV16 E6 or HPV18 E6 DNA. Positive control 2, 50 ng Hela cell DNA. Negative control 1, pure
water. Negative control 2, pure water instead of 2 ×master mixture. Negative control 3, pure water instead of positive control DNA
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tissue and serum samples of Chinese OSCC and OPMD
patients [21]. We conducted complementary analyses to
verify the results of the real-time PCR with DNA sequen-
cing. We found that none of the patients with OSCC or
OPMD demonstrated existence of high-risk HPV16 or
HPV18. The absence of HPV DNA in our sample implies
that HPV infection may not be common in Chinese pa-
tients with OSCC and OPMD.
A critical step in malignant transformation is the inte-
gration of high-risk HPV DNA into the human cellular
genome, followed by the expression of the oncoproteins
E6 and E7, which promote tumor progression [21]. In a
previous study, although the reported detection rate of
high-risk HPV DNA in OSCC was 6.6 %, HPV mRNA
was only detected in 5.9 % [22]. These findings indicated
that the mRNA or oncoproteins of HPV E6 and E7 were
less commonly found than the DNA, as the presence of
HPV in the genome differed from the HPV-related eti-
ology [23, 24]. The gold standard to identify the pres-
ence of HPV was therefore suggested to be detecting
HPV DNA [25].
Yadav et al. showed that the HPV DNA detection limit
for conventional PCR was 200 copies, whereas for real-
time PCR, which has a higher sensitivity, detecting HPV
DNA required only 1 copy [26]. Lingen et al. detected
high-risk HPV DNA in 9.8 % of OSCC cases using con-
sensus primer PCR, but the positive rate was 6.6 % using
real-time PCR [22]. Scapoli et al. found the detection
rate of HPV16 to be 2 % in OSCC with real-time PCR
[27]. Real-time PCR shows a higher sensitivity and speci-
ficity than conventional PCR assays [12, 22, 26]. In the
current study, we utilized real-time PCR and found that
3 of 198 samples showed late and deformed amplifying
curves of HPV 16 E6 and 7 of 198 samples had late and
deformed amplifying curves of HPV 18 E6. To rule out
false positives, we performed subsequent sequencing and
found that the rate of false positives using real-time PCR
to detect HPV16 E6 and HPV18 E6 DNA was 1.52 and
3.54 %, respectively. Ha et al. found a 2 % false-positive
rate for real-time PCR using the minimum criteria of
HPV DNA copy number, which was similar to our re-
sults [12].
The population has also been considered to be another
factor affecting rate diversification. Several countries
have revealed a zero detection rate of OSCC, including
India [28–30], Brazil [31], Japan [32] and Mozambique
[33]. Other reported detection rates have been 1.54 % in
Thailand [34], 6.6 % in America [22], 5 % in Mexico
[35], 39.4 % in Spain [36] and 66.7 % in Sudan [37].
Studies performed in China have yielded varied results
using conventional PCR assays, ranging from 2.2 to 74 %
[38–42]. However, real-time PCR data for OSCC has not
been reported in China. Our study revealed a zero detec-
tion rate of HPV16 and 18 in OSCC by combining real-
time PCR and DNA sequencing, which was a reliable
method and provided further understanding of HPV in-
fection in Chinese patients.
HPV infection has been identified in cancers of the cer-
vix [43], vulva [44], vagina [44], anus [44], penis [45] and
oropharynx [46]. It is widely accepted that OPSCCs, espe-
cially tonsillar cancers, are frequently associated with HPV
infection [17]. The recent reported prevalence of HPV in
OPSCC was approximately 60-70 % [47], but the corre-
sponding rate was substantially lower and significantly
varied in OSCC [8, 17]. HPV prevalence in OPSCC has
been suggested to be an independent prognostic factor
[47]. HPV-positive OPSCC has been shown to be dis-
tinct from HPV-negative OPSCC with regard to prog-
nosis [48–50]. However, there have been no direct
correlations between HPV infection and oral carcino-
genesis [23, 27, 51].
HPV has been detected not only in cancer but also in
premalignant lesions, such as in lesions of the cervix and
breast [9, 52, 53]. In contrast, there was a lack of HPV in
premalignant lesions of the colon [54–56]. Interestingly,
A B
Fig. 2 Standard curves for HPV16 and HPV 18 E6. a Standard curves for 10-fold diluted HPV16 E6 plasmid DNA ranging from 0.1 ng/well to 0.1 pg/well;
b Standard curves for 10-fold diluted HPV18 E6 plasmid DNA ranging from 1 ng/well to 0.1 pg/well
Table 2 Sequence of HPV16 and HPV18 E6 primers and ACTB
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Ha et al. demonstrated a low prevalence (1.1 %) of HPV16
in OPMD [12]. Similarly, we detected no presence of HPV
16 and 18 in Chinese patients with OPMD.
Conclusion
Overall, we demonstrated a prevalence rate of 0 % of HPV
16 and 18 in Chinese patients with OSCC and OPMD.
Our data suggests that high-risk HPV16 and HPV18 in-
fection may not be common in Chinese patients with
OSCC and OPMD. Combining real-time PCR and DNA
sequence for HPV DNA detection is an effective strat-
egy to eliminate false positives.
Abbreviations
HNSCC: head and neck squamous cell carcinoma; HPV: human
papillomavirus; OPSCC: oropharynx squamous cell carcinoma; OSCC: oral
squamous cell carcinoma.
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